These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 17855664)
1. Increased expression of corepressors in aggressive androgen-independent prostate cancer cells results in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness. Ting HJ; Bao BY; Reeder JE; Messing EM; Lee YF Mol Cancer Res; 2007 Sep; 5(9):967-80. PubMed ID: 17855664 [TBL] [Abstract][Full Text] [Related]
2. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. Bao BY; Hu YC; Ting HJ; Lee YF Oncogene; 2004 Apr; 23(19):3350-60. PubMed ID: 15048085 [TBL] [Abstract][Full Text] [Related]
3. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells. Khanim FL; Gommersall LM; Wood VH; Smith KL; Montalvo L; O'Neill LP; Xu Y; Peehl DM; Stewart PM; Turner BM; Campbell MJ Oncogene; 2004 Sep; 23(40):6712-25. PubMed ID: 15300237 [TBL] [Abstract][Full Text] [Related]
4. Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progression. Godoy AS; Sotomayor PC; Villagran M; Yacoub R; Montecinos VP; McNerney EM; Moser M; Foster BA; Onate SA Biochem Biophys Res Commun; 2012 Jul; 423(3):564-70. PubMed ID: 22695118 [TBL] [Abstract][Full Text] [Related]
6. 1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells. Serda RE; Bisoffi M; Thompson TA; Ji M; Omdahl JL; Sillerud LO Prostate; 2008 May; 68(7):773-83. PubMed ID: 18247401 [TBL] [Abstract][Full Text] [Related]
7. 1,25-dihydroxyvitamin D3 transcriptionally represses p45Skp2 expression via the Sp1 sites in human prostate cancer cells. Huang YC; Hung WC J Cell Physiol; 2006 Nov; 209(2):363-9. PubMed ID: 16883603 [TBL] [Abstract][Full Text] [Related]
8. Epigenetic repression of transcription by the Vitamin D3 receptor in prostate cancer cells. Gommersall LM; Khanim FL; Peehl DM; Doherty AH; Campbell MJ J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):251-6. PubMed ID: 15225780 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1alpha-hydroxyvitamin D5. Peng X; Jhaveri P; Hussain-Hakimjee EA; Mehta RG Carcinogenesis; 2007 May; 28(5):1000-7. PubMed ID: 17130524 [TBL] [Abstract][Full Text] [Related]
10. The role of long-chain fatty-acid-CoA ligase 3 in vitamin D3 and androgen control of prostate cancer LNCaP cell growth. Qiao S; Tuohimaa P Biochem Biophys Res Commun; 2004 Jun; 319(2):358-68. PubMed ID: 15178414 [TBL] [Abstract][Full Text] [Related]
11. Growth inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31. Moffatt KA; Johannes WU; Hedlund TE; Miller GJ Cancer Res; 2001 Oct; 61(19):7122-9. PubMed ID: 11585744 [TBL] [Abstract][Full Text] [Related]
12. Identification of VDR-responsive gene signatures in breast cancer cells. Towsend K; Trevino V; Falciani F; Stewart PM; Hewison M; Campbell MJ Oncology; 2006; 71(1-2):111-23. PubMed ID: 17377416 [TBL] [Abstract][Full Text] [Related]
13. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells. Sertznig P; Dunlop T; Seifert M; Tilgen W; Reichrath J Anticancer Res; 2009 Sep; 29(9):3647-58. PubMed ID: 19667161 [TBL] [Abstract][Full Text] [Related]
14. Down-regulation of NF-kappaB signals is involved in loss of 1alpha,25-dihydroxyvitamin D3 responsiveness. Bao BY; Ting HJ; Hsu JW; Yasmin-Karim S; Messing E; Lee YF J Steroid Biochem Mol Biol; 2010 May; 120(1):11-21. PubMed ID: 20206692 [TBL] [Abstract][Full Text] [Related]
15. Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells. Banwell CM; MacCartney DP; Guy M; Miles AE; Uskokovic MR; Mansi J; Stewart PM; O'Neill LP; Turner BM; Colston KW; Campbell MJ Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2004-13. PubMed ID: 16609009 [TBL] [Abstract][Full Text] [Related]
16. The first locked side-chain analogues of calcitriol (1alpha,25-dihydroxyvitamin D3) induce vitamin D receptor transcriptional activity. Pérez-García X; Rumbo A; Larriba MJ; Ordóñez P; Muñoz A; Mouriño A Org Lett; 2003 Oct; 5(22):4033-6. PubMed ID: 14572242 [TBL] [Abstract][Full Text] [Related]
17. 1alpha,25-Dihydroxyvitamin D3-3beta-(2)-bromoacetate, an affinity labeling derivative of 1alpha,25-dihydroxyvitamin D3 displays strong antiproliferative and cytotoxic behavior in prostate cancer cells. Swamy N; Persons KS; Chen TC; Ray R J Cell Biochem; 2003 Aug; 89(5):909-16. PubMed ID: 12874825 [TBL] [Abstract][Full Text] [Related]
18. MAPK inhibition by 1alpha,25(OH)2-Vitamin D3 in breast cancer cells. Evidence on the participation of the VDR and Src. Rossi AM; Capiati DA; Picotto G; Benassati S; Boland RL J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):287-90. PubMed ID: 15225787 [TBL] [Abstract][Full Text] [Related]
19. Targeting 1alpha,25-dihydroxyvitamin D3 antiproliferative insensitivity in breast cancer cells by co-treatment with histone deacetylation inhibitors. Banwell CM; O'Neill LP; Uskokovic MR; Campbell MJ J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):245-9. PubMed ID: 15225779 [TBL] [Abstract][Full Text] [Related]
20. Differential biological effects of 1,25-dihydroxyVitamin D3 on melanoma cell lines in vitro. Seifert M; Rech M; Meineke V; Tilgen W; Reichrath J J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):375-9. PubMed ID: 15225804 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]